SAGE Therapeutics (SAGE) Lifted to Hold at BidaskClub

SAGE Therapeutics (NASDAQ:SAGE) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Saturday.

SAGE has been the topic of a number of other research reports. Stifel Nicolaus restated a “buy” rating and set a $198.00 price target on shares of SAGE Therapeutics in a report on Friday, December 8th. Needham & Company LLC boosted their price target on SAGE Therapeutics from $86.00 to $100.00 and gave the company a “buy” rating in a report on Friday, November 10th. BMO Capital Markets restated a “buy” rating and set a $80.00 price target on shares of SAGE Therapeutics in a report on Friday, October 27th. Goldman Sachs Group restated a “buy” rating and set a $87.00 price target on shares of SAGE Therapeutics in a report on Friday, October 6th. Finally, Chardan Capital upgraded SAGE Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $60.00 to $140.00 in a report on Friday, November 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $171.21.

SAGE Therapeutics (NASDAQ:SAGE) opened at $186.78 on Friday. SAGE Therapeutics has a twelve month low of $46.11 and a twelve month high of $195.97. The stock has a market capitalization of $7,895.92, a PE ratio of -27.19 and a beta of 2.98.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.98) by $0.01. The firm’s quarterly revenue was up .0% on a year-over-year basis. analysts forecast that SAGE Therapeutics will post -7.42 earnings per share for the current year.

In other SAGE Therapeutics news, insider Stephen Kanes sold 44,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $177.18, for a total transaction of $7,795,920.00. Following the transaction, the insider now owns 46,348 shares in the company, valued at approximately $8,211,938.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total value of $33,103,390.15. Following the transaction, the chief executive officer now owns 211,473 shares in the company, valued at approximately $33,296,423.85. The disclosure for this sale can be found here. Insiders have sold a total of 314,247 shares of company stock worth $50,465,110 in the last quarter. Company insiders own 6.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of SAGE Therapeutics by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock worth $219,006,000 after purchasing an additional 58,679 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of SAGE Therapeutics by 36.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after purchasing an additional 724,494 shares in the last quarter. State Street Corp boosted its position in shares of SAGE Therapeutics by 7.7% in the 2nd quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock worth $96,558,000 after purchasing an additional 87,097 shares in the last quarter. Oak Ridge Investments LLC boosted its position in shares of SAGE Therapeutics by 0.9% in the 3rd quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock worth $45,897,000 after purchasing an additional 6,835 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of SAGE Therapeutics by 17.9% in the 2nd quarter. Northern Trust Corp now owns 411,444 shares of the biopharmaceutical company’s stock worth $32,767,000 after purchasing an additional 62,474 shares in the last quarter. 95.48% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/03/sage-therapeutics-sage-lifted-to-hold-at-bidaskclub.html.

About SAGE Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply